Solos Endoscopy Announces the MammoView(R) Breast
Post# of 1609
Posted On: 11/07/2013 10:15:52 AM
Solos Endoscopy Announces the MammoView(R) Breast Cancer Global Initiative for 2014
BOSTON, MA -- (Marketwired) -- 11/07/13 -- Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce its new MammoView® Breast Cancer Global Initiative for 2014. Solos Endoscopy plans to work with various breast cancer awareness campaigns year round to continue building upon the public's "brand awareness" for breast cancer; its detection, its treatment, and the need for a reliable, permanent cure.
Increased awareness has resulted in more women receiving mammograms, the number of breast cancers detected, and the number of women receiving biopsies. Solos Endoscopy believes that as a result of awareness, breast cancers are being detected at an earlier, more treatable stage. Awareness efforts have successfully utilized marketing approaches to reduce the stigma associated with the disease.
However, more work needs to be done. As part of the new MammoView® Breast Cancer Global Initiative, Solos Endoscopy plans to team up with the various charities and foundations who are promoting "Breast Cancer Awareness" and educate them about the clinical benefits of the MammoView® instrument line and breast ductoscopy. The Solos Endoscopy MammoView® Breast Endoscopy System can offer women a positive prognosis for recovery by detecting breast cancer up to six times faster than conventional methods. The MammoView® instrument line allows physicians to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods.
"The MammoView® Breast Cancer Global Initiative is more than just awareness, it's about education, and choices for women. October is over; people and businesses nationwide will take down their pink ribbons and pink signs, yet women all over the world will still be battling breast cancer. Solos Endoscopy will continue its efforts to fight breast cancer not just in October but throughout the year," stated Robert Segersten, President of Solos Endoscopy.
Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView® instrument line with proper approval which will allow the instrument line to be sold globally starting in 2014.
Thanks to blueskies for posting!
BOSTON, MA -- (Marketwired) -- 11/07/13 -- Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce its new MammoView® Breast Cancer Global Initiative for 2014. Solos Endoscopy plans to work with various breast cancer awareness campaigns year round to continue building upon the public's "brand awareness" for breast cancer; its detection, its treatment, and the need for a reliable, permanent cure.
Increased awareness has resulted in more women receiving mammograms, the number of breast cancers detected, and the number of women receiving biopsies. Solos Endoscopy believes that as a result of awareness, breast cancers are being detected at an earlier, more treatable stage. Awareness efforts have successfully utilized marketing approaches to reduce the stigma associated with the disease.
However, more work needs to be done. As part of the new MammoView® Breast Cancer Global Initiative, Solos Endoscopy plans to team up with the various charities and foundations who are promoting "Breast Cancer Awareness" and educate them about the clinical benefits of the MammoView® instrument line and breast ductoscopy. The Solos Endoscopy MammoView® Breast Endoscopy System can offer women a positive prognosis for recovery by detecting breast cancer up to six times faster than conventional methods. The MammoView® instrument line allows physicians to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods.
"The MammoView® Breast Cancer Global Initiative is more than just awareness, it's about education, and choices for women. October is over; people and businesses nationwide will take down their pink ribbons and pink signs, yet women all over the world will still be battling breast cancer. Solos Endoscopy will continue its efforts to fight breast cancer not just in October but throughout the year," stated Robert Segersten, President of Solos Endoscopy.
Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView® instrument line with proper approval which will allow the instrument line to be sold globally starting in 2014.
Thanks to blueskies for posting!
(0)
(0)